Atogepant for the prevention of episodic migraine in adults
Objective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods: The authors performed a systematic search for sources, including articles, abstracts, and poster presentations. Quer...
Main Authors: | Maranda Paige Switzer, Joseph Edward Robinson, Kayla Rena Joyner, Kelsey Woods Morgan |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-10-01
|
Series: | SAGE Open Medicine |
Online Access: | https://doi.org/10.1177/20503121221128688 |
Similar Items
-
Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
by: Cohen F, et al.
Published: (2022-04-01) -
Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
by: Kelsey Woods Morgan, et al.
Published: (2021-10-01) -
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
by: Xinyu Tao, et al.
Published: (2022-01-01) -
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
by: Paul Rizzoli, et al.
Published: (2024-03-01) -
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
by: K. Chris Min, et al.
Published: (2021-03-01)